BioArctic
Manufacturing · Sweden · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Warfvinges Väg 35, Stockholm, Stockholm,...Phone Number
+46 86956930Website
www.bioarctic.comRevenue
$157.8 MillionStock Symbol
BIOA-BIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About BioArctic
BioArctic is a Swedish research oriented biopharma company. Based on our cutting-edge expertise in neurodegenerative disorders, we have built a broad and well-diversified project portfolio with the potential to improve the health of patients. The diversity of projects in various phases of development provides a solid basis for creating value for patients, their families, and society as a whole. This makes us an attractive company to both partners and investors.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioArctic your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when BioArctic launches new products
Check if BioArctic has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if BioArctic had a recent Job posting/layoffs
Check out if BioArctic is spiking on competitors!
BioArctic, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at BioArctic
Earning: See what the market has to say on BioArctic recently announced quarterly report
Funding: Get notified immidiatlly once BioArctic has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
BioArctic is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioArctic is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioArctic.
BioArctic Tech Stack
A closer look at the technologies used by BioArctic
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Product Development, Product Management, Governmental Affairs & Regulation, Pharmaceuticals, Regulations
Product Launch
BioArctic announced that Leqembi has been approved by 17 health authorities globally, covering 49 countries. The European launch has begun in Austria, with Germany following next week, and a gradual rollout planned throughout 2026-2027. In the Nordics, dossiers have been submitted to authorities in 4 countries to start the pricing and reimbursement process.
Product Launch, Medical Research, Pharmaceuticals
Project
BioArctic announced that its alpha-synuclein antibody, lecanemab, has progressed to higher doses in both Parkinson's and MSA patients in its phase 2a study. The company has also received orphan designation for lecanemab for MSA in both the U.S. and EU.
Medical Research, Pharmaceuticals
Project
Medical Research, Pharmaceuticals
BioArctic News & Media
Bulletin from the Annual General Meeting in BioArctic AB (publ)
STOCKHOLM, May 28, 2026 /PRNewswire/ -- Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm, whereby the following resolutions were made. Adoption of the income statement and the balance sheet: allocation of result and determination of the...Bulletin from the Annual General Meeting in BioArctic AB (publ)
STOCKHOLM, May 28, 2026 /PRNewswire/ -- Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm, whereby the following resolutions were made. Adoption of the income statement and the balance sheet: allocation of result and determination of the...BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day
STOCKHOLM, May 25, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi. According to Eisai's simulation, Leqembi sales will reach around JPY 300 billion...BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day
STOCKHOLM, May 25, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi. According to Eisai's simulation, Leqembi sales will reach around JPY 300 billion...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding BioArctic
Sign Up For FreeTo access detailed company insights
BioArctic is a Swedish research oriented biopharma company. Based on our cutting-edge expertise in neurodegenerative disorders, we have built a broad and well-diversified project portfolio with the potential to improve the health of patients. The diversity of projects in various phases of development provides a solid basis for creating value for pa... Read More
